



Using Mentzer Index to Improve Anemia Management in Pregnancy: A Narrative Review

Emmanuel Ifeanyi Obeagu *

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

Article Info:

Article History:

Received 02 Nov 2024

Reviewed 11 Dec 2024

Accepted 09 Jan 2025

Published 15 March 2025

Cite this article as:

Obeagu EI, Using Mentzer Index to Improve Anemia Management in Pregnancy: A Narrative Review, Asian Journal of Dental and Health Sciences. 2025; 5(1):1-4

DOI: <http://dx.doi.org/10.22270/ajdhs.v5i1.106>

Abstract

Anemia during pregnancy is a significant public health challenge, affecting maternal well-being and fetal development. Among the most common causes are iron deficiency anemia (IDA) and thalassemia trait (TT), conditions requiring distinct management strategies. Accurate differentiation between these conditions is critical, as misdiagnosis can lead to suboptimal treatment outcomes. The Mentzer Index, calculated by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count, offers a simple and reliable tool for distinguishing between IDA and TT, especially in resource-limited settings. This review explores the utility of the Mentzer Index in improving anemia diagnosis and management in pregnancy. By analyzing routine complete blood count (CBC) results, the Mentzer Index allows for initial differentiation, facilitating timely and appropriate interventions. A Mentzer Index value of ≥ 13 indicates IDA, guiding clinicians toward iron supplementation, while a value < 13 suggests TT, prompting further investigations and genetic counseling. This approach reduces unnecessary interventions, improves diagnostic accuracy, and ensures tailored management, mitigating complications such as preterm birth, low birth weight, and maternal morbidity.

Keywords: Mentzer Index, pregnancy, anemia, iron deficiency, thalassemia

*Address for Correspondence:

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

Introduction

Anemia in pregnancy is a global health concern, particularly in low- and middle-income countries, where it affects nearly 40% of pregnant women. This condition is associated with significant maternal and fetal complications, including maternal fatigue, increased risk of infections, preterm birth, low birth weight, and perinatal mortality. Anemia during pregnancy is a multifactorial condition, with iron deficiency anemia (IDA) and thalassemia trait (TT) representing the most common etiologies. Accurate differentiation between these two types of anemia is critical, as their management strategies differ significantly, and misdiagnosis can exacerbate complications or lead to unnecessary interventions.¹⁻³ Iron deficiency anemia (IDA) is the most prevalent form of anemia worldwide, characterized by reduced red blood cell production due to insufficient iron availability. IDA commonly results from increased iron demands during pregnancy, coupled with inadequate dietary intake or chronic blood loss. In contrast, thalassemia trait (TT) is a genetic condition associated with impaired hemoglobin production, resulting in microcytosis and hypochromia. While IDA typically responds well to iron supplementation, the treatment for TT is more complex, involving genetic counseling, prenatal screening, and

the prevention of unnecessary iron overload. Therefore, distinguishing between IDA and TT is essential for effective patient management.⁴⁻⁶ The Mentzer Index has emerged as a practical tool for differentiating between IDA and TT in clinical practice. Calculated by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count, this index provides a simple and cost-effective method for initial screening. A Mentzer Index value of ≥ 13 is indicative of IDA, while a value < 13 suggests TT. Its reliance on parameters obtained from routine complete blood count (CBC) tests makes it an accessible and low-cost option, especially in resource-constrained settings where advanced diagnostic tools such as hemoglobin electrophoresis or genetic testing may not be readily available.⁷ In addition to its practicality, the Mentzer Index addresses several challenges associated with anemia diagnosis in pregnancy. It helps reduce diagnostic delays, enabling timely and appropriate interventions. Early differentiation between IDA and TT prevents complications arising from mistreatment, such as the risk of iron overload in patients with TT who are mistakenly prescribed iron supplements. Furthermore, the Mentzer Index supports informed decision-making in antenatal care, allowing clinicians to implement tailored interventions that align with the underlying cause of anemia.⁸

The Role of the Mentzer Index in Anemia Diagnosis

Calculation and Interpretation

The Mentzer Index is a simple mathematical calculation derived from routine complete blood count (CBC) results. It is obtained by dividing the mean corpuscular volume (MCV) by the red blood cell (RBC) count, expressed in millions per microliter (μL). This calculation provides a numerical value that aids in distinguishing between iron deficiency anemia (IDA) and thalassemia trait (TT), two common causes of anemia. A Mentzer Index value of ≥ 13 suggests IDA, as this condition is typically associated with low MCV and RBC count. Conversely, a value < 13 is indicative of TT, characterized by low MCV but a normal or elevated RBC count.⁹ The accessibility of the Mentzer Index lies in its simplicity and reliance on routinely performed CBC tests. This makes it an attractive tool in resource-limited settings where advanced diagnostic techniques such as hemoglobin electrophoresis or genetic testing are often unavailable. Additionally, its non-invasive nature and ease of calculation enable widespread adoption, even in primary care settings.¹⁰

Application in Pregnancy

During pregnancy, anemia is frequently encountered and can have profound consequences for both mother and child. The Mentzer Index serves as a valuable tool in differentiating between IDA and TT, aiding clinicians in making informed treatment decisions. In cases of IDA, elevated Mentzer Index values direct healthcare providers toward iron supplementation, addressing the underlying deficiency. For TT, a low Mentzer Index value highlights the need for genetic counseling and avoidance of unnecessary iron supplementation, which could lead to iron overload.¹¹

Benefits in Clinical Practice

Incorporating the Mentzer Index into anemia diagnosis during pregnancy offers multiple benefits. It facilitates early differentiation between IDA and TT, reducing delays in initiating appropriate therapy. This is particularly important in pregnancy, where untreated anemia can lead to adverse outcomes such as preterm delivery, intrauterine growth restriction, and increased maternal morbidity. Furthermore, the Mentzer Index minimizes the risk of over-treatment, ensuring that iron supplementation is reserved for those who will benefit from it, while patients with TT receive appropriate genetic evaluation and counseling.¹²

Implications for Anemia Management

Tailored Treatment Approaches

The use of the Mentzer Index in anemia diagnosis allows for tailored treatment strategies that address the specific underlying cause of anemia in pregnant women. In cases of iron deficiency anemia (IDA), characterized by a Mentzer Index value of ≥ 13 , treatment focuses on iron supplementation. This approach replenishes iron stores, improves hemoglobin levels, and reduces symptoms such as fatigue and dizziness, which can

impact maternal quality of life and fetal growth. In contrast, a Mentzer Index value < 13 , indicative of thalassemia trait (TT), highlights the importance of avoiding unnecessary iron supplementation, which could lead to iron overload and associated complications. Instead, patients with TT benefit from genetic counseling and prenatal screening to assess the risk of severe hemoglobinopathies in the fetus.¹³

Reducing Diagnostic Delays

Anemia during pregnancy is associated with significant maternal and fetal risks, including preterm birth, low birth weight, and increased perinatal mortality. The Mentzer Index facilitates early differentiation between IDA and TT, enabling clinicians to initiate appropriate management promptly. This reduces delays caused by waiting for confirmatory tests and helps mitigate complications that arise from untreated anemia. Moreover, the ability to distinguish anemia types using a simple, accessible tool ensures timely interventions, particularly in resource-constrained settings where diagnostic resources may be limited.¹⁴

Enhancing Cost-Effectiveness

In regions with limited healthcare infrastructure, advanced diagnostic tools such as hemoglobin electrophoresis or genetic testing may be unavailable or unaffordable. The Mentzer Index offers a cost-effective alternative for initial screening. Its reliance on routinely available complete blood count (CBC) parameters makes it accessible to a broader population, reducing financial barriers to care. By identifying patients who require confirmatory testing or specific interventions, the Mentzer Index helps allocate healthcare resources more efficiently, ensuring that advanced diagnostic services are reserved for cases where they are most needed.¹⁵

Supporting Comprehensive Care

Incorporating the Mentzer Index into anemia management during pregnancy aligns with the principles of comprehensive antenatal care. It facilitates a holistic approach to maternal health by combining initial screening with confirmatory tests and lifestyle interventions. For IDA, this may include dietary counseling to improve iron intake and addressing contributing factors such as gastrointestinal blood loss. For TT, the focus shifts to genetic counseling, family planning, and monitoring fetal hemoglobin status. By addressing the root causes of anemia, the Mentzer Index contributes to sustainable improvements in maternal and fetal outcomes.¹⁶

Implications for Public Health

Widespread adoption of the Mentzer Index can significantly impact public health, particularly in low- and middle-income countries where anemia prevalence is high. Its use as a routine screening tool in antenatal care programs can help identify anemia cases early, ensuring that interventions are initiated before complications arise. Additionally, its simplicity and accessibility make it an ideal candidate for training healthcare workers in primary care settings,

empowering them to provide effective maternal care and improve community health outcomes.¹⁷

Challenges and Limitations

Diagnostic Ambiguity in Mixed Anemia

One of the primary limitations of the Mentzer Index is its inability to accurately diagnose mixed anemia, where iron deficiency anemia (IDA) coexists with thalassemia trait (TT). In such cases, the red blood cell (RBC) count and mean corpuscular volume (MCV) values may not clearly align with the expected ranges for IDA or TT, leading to intermediate or misleading Mentzer Index values. This ambiguity can complicate the diagnostic process, necessitating further confirmatory testing, such as serum ferritin measurements or hemoglobin electrophoresis, to determine the precise etiology of anemia.¹⁸

Influence of Concurrent Conditions

The accuracy of the Mentzer Index can be influenced by concurrent medical conditions that affect RBC parameters. Chronic infections, inflammation, or other underlying diseases can alter the MCV or RBC count, potentially skewing the index value. For example, in inflammatory states, changes in iron metabolism may mask or mimic the characteristics of IDA. These factors can limit the reliability of the Mentzer Index, particularly in pregnant women with multiple comorbidities, underscoring the need for comprehensive clinical evaluation and additional diagnostic tools.¹⁹⁻²⁰

Limited Scope as a Screening Tool

While the Mentzer Index is a valuable screening tool, it is not a definitive diagnostic method. Its simplicity, though advantageous, also restricts its ability to capture the complexity of anemia pathophysiology. For example, the index does not differentiate between different forms of thalassemia or detect other less common causes of anemia, such as vitamin B12 or folate deficiencies. Its use is therefore limited to preliminary differentiation between IDA and TT, necessitating further investigations to confirm the diagnosis and guide treatment.²¹⁻²²

Challenges in Low-Resource Settings

Although the Mentzer Index is cost-effective and accessible, its reliance on accurate and high-quality complete blood count (CBC) results can pose challenges in low-resource settings. Poorly calibrated laboratory equipment or lack of trained personnel may compromise the reliability of the RBC count and MCV values, leading to erroneous index calculations. Additionally, the unavailability of follow-up confirmatory tests, such as ferritin assays or hemoglobin electrophoresis, may hinder the effective use of the Mentzer Index in guiding treatment decisions.²³⁻²⁴

Risk of Over-Reliance

Over-reliance on the Mentzer Index without confirmatory testing can lead to misdiagnosis and

inappropriate management. For instance, patients with a falsely elevated index value may be misclassified as having IDA and treated with unnecessary iron supplementation, potentially resulting in iron overload in those with TT. Conversely, underestimating the complexity of anemia in patients with mixed etiologies could delay appropriate interventions, increasing the risk of maternal and fetal complications.²⁵⁻²⁶

Need for Training and Awareness

The successful application of the Mentzer Index in clinical practice requires adequate training of healthcare providers. Misinterpretation of the index or lack of awareness about its limitations can reduce its diagnostic utility. Educational initiatives are essential to ensure that clinicians understand when and how to use the Mentzer Index effectively, as well as the importance of complementing it with additional diagnostic methods.²⁷

Conclusion

The Mentzer Index serves as a valuable and accessible tool for the initial evaluation of anemia during pregnancy, offering a simple and cost-effective method to differentiate between iron deficiency anemia (IDA) and thalassemia trait (TT). Its reliance on routinely performed complete blood count (CBC) parameters makes it particularly advantageous in resource-limited settings where advanced diagnostic facilities are unavailable. By enabling timely and accurate identification of the anemia type, the Mentzer Index facilitates targeted interventions that improve maternal and fetal health outcomes. However, the Mentzer Index is not without its challenges. Its diagnostic accuracy can be affected by mixed anemia, concurrent medical conditions, and limitations inherent to the index itself, such as its inability to differentiate between all forms of anemia. Over-reliance on the index without confirmatory testing risks misdiagnosis and inappropriate management. Therefore, its application should be complemented by additional diagnostic tests, including serum ferritin measurements, hemoglobin electrophoresis, and genetic counseling when necessary.

Conflict of Interest: Author declares no potential conflict of interest with respect to the contents, authorship, and/or publication of this article.

Source of Support: Nil

Funding: The authors declared that this study has received no financial support.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting in this paper are available in the cited references.

Ethics approval: Not applicable.

References

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. *The American journal of*

- clinical nutrition. 2016; 103(2):495-504.
<https://doi.org/10.3945/ajcn.115.107896> PMID:26739036
2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. *Int J Curr Res Chem Pharm Sci*. 2016;3(3):10-18. <https://doi.org/10.22270/ijmspr.v10i2.95>
 3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206.
 4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. *International journal of women's health*. 2016;441-451.
<https://doi.org/10.2147/IJWH.S89308> PMID:27660493
PMCID:PMC5019437
 5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. *J Res Med Dent Sci*. 2021 Apr;9(4):145-148.
 6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. *Journal of Public Health and Nutrition*. 2023;6(1):138.
 7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new indices for differentiation between iron deficiency anemia and beta thalassemia trait, a study in pregnant females. *International Journal of Scientific Reports*. 2018; 4(2):26.
<https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394>
 8. Obeagu EI, Obeagu GU, Insights into Maternal Health: Mentzer Index for Early Anemia Detection, *International Journal of Medical Sciences and Pharma Research*, 2024;10(4):44-49
<https://doi.org/10.22270/ijmspr.v10i4.122>
 9. Obeagu EI, Influence of Hemoglobin Variants on Vaso-Occlusive Phenomena in Sick Cell Anemia: A Review, *International Journal of Medical Sciences and Pharma Research*, 2024;10(2):54-59
<https://doi.org/10.22270/ijmspr.v10i2.104>
 10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou-Fakhredin R, Muckenthaler MU, Unal S, Porto G. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. *Hemasphere*. 2024; 8(7):e108.
<https://doi.org/10.1002/hem3.108> PMID:39011129
PMCID:PMC11247274
 11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022 Apr 19;2(2):1-9.
 12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*, 2024; 2(3): 38-58
 13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: differentiation between β -thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2013; 51(11):2115-24. <https://doi.org/10.1515/cclm-2013-0354> PMID:23800659
 14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2015; 53(12):2015-9.
<https://doi.org/10.1515/cclm-2015-0155> PMID:26536583
 15. Miftahussurur M, Husada D, Ningtyas WS. Association Association Of Shine and Lal Index B-Thalassemia Trait Screening Results with Anaemia and Low Birth Weigh. *International Journal of Nursing And Midwifery Science (IJNMS)*. 2023; 7(3):290-296.
<https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543>
 16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. Evaluation of Srivastava index to distinguishing Beta-Thalassemia Trait from Iron Deficiency. *Pakistan Journal of Medical & Health Sciences*. 2022;16(05):1225.
<https://doi.org/10.53350/pjmhs221651225>
 17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, Turkmen S, Kacan A. Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia. *Anemia*. 2014; 2014(1):576738.
<https://doi.org/10.1155/2014/576738> PMID:24818016
PMCID:PMC4003757
 18. Urrechaga E. Discriminant value of % microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. *Clinical chemistry and laboratory medicine*. 2008;46(12):1752-1758.
<https://doi.org/10.1515/CCLM.2008.355> PMID:19055451
 19. Obeagu EI, Obeagu GU, Anemia in Pregnancy: Mentzer Index as a Predictor for Iron Supplementation Needs, *International Journal of Medical Sciences and Pharma Research*, 2024;10(4):39-43
<https://doi.org/10.22270/ijmspr.v10i4.121>
 20. Obeagu EI, Obeagu GU. Sick cell anaemia in pregnancy: a review. *International Research in Medical and Health Sciences*. 2023 Jun 10;6(2):10-13. <https://doi.org/10.22270/ijmspr.v10i2.103>
 21. Obeagu EI, Ubosi NI, Uzoma G. Antioxidant Supplementation in Pregnancy: Effects on Maternal and Infant Health. *Int. J. Adv. Multidiscip. Res*. 2023;10(11):60-70.
 22. Obeagu EI, Obeagu GU. Mitigating Oxidative Stress in Pregnancy through Antioxidant Supplementation: A Narrative Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(9):7-17.
 23. Obeagu EI, Obeagu GU. Enhancing Maternal and Fetal Well-being: The Role of Antioxidants in Pregnancy. *Elite Journal of Medical Sciences*. 2024;2(4):76-87.
 24. Obeagu EI, Obeagu GU. Antioxidant Supplementation and Prevention of Early Pregnancy Loss: A Narrative Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(9):28-37.
<https://doi.org/10.22270/ijmspr.v10i4.120>
 25. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(7):25-28.
<https://doi.org/10.19080/IJGWH.2023.25.556169>
 26. Obeagu EI, Obeagu GU. Hypoxia-induced Metabolic Changes in Pregnancy: Clinical Perspectives. *Elite Journal of Medicine*. 2024;2(8):50-59.
 27. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sick Cell Anemia: A Review. *Elite Journal of Haematology*. 2024;2(3):67-80.